Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy

Mitsuhiro Hirode, Ko Omura, Naoki Kiyosawa, Takeki Uehara, Toshinobu Shimuzu, Atsushi Ono, Toshikazu Miyagishima, Taku Nagao, Yasuo Ohno, Tetsuro Urushidani

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)


A large-scale transcriptome database of rat liver (TG-GATEs) has been established by the Toxicogenomics Project in Japan. In the present study, we focused on 8 hepatotoxic compounds within TG-GATEs, i.e., clofibrate, omeprazole, ethionine, thioacetamide, benzbromarone, propylthiouracil, Wy-14,643 and amiodarone, which induced coagulation abnormalities. Aspirin was selected as a reference compound that directly causes coagulation abnormality, but not through liver toxicity. In blood chemical examinations, for all the coagulopathic compounds there was little elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT), suggesting no severe cell death by treatment with the compounds. We extracted 344 probe sets from the data for these 8 typical drugs, which induced this phenotype at any time from 3 to 28 days of repeated administration. Principal component analysis using these probe sets clearly separated dose- and time-dependent clusters of the treated groups from their controls, except aspirin and propylthiouracil, both of which were considered to cause coagulopathy not due to their hepatotoxicity but due to their direct effects on the blood coagulation system. Reviewing the extracted genes, changes in lipid metabolism were found to be dominant. Genes related to blood coagulation were generally down-regulated by these drugs except that vitamin K epoxide reductase complex subunit 1 (Vkorc1) like 1, a paralogous gene of Vkorc1, was up-regulated. As expected, expression changes of these genes were least prominent in aspirin or propylthiouracil-treated liver. We concluded that these probe sets could be a good starting point in developing mechanism-based biomarkers for diagnosis or prognosis of hcpatotoxicity-related coagulation abnormalities in the early stage of drug development.

Original languageEnglish
Pages (from-to)281-293
Number of pages13
JournalJournal of Toxicological Sciences
Issue number3
Publication statusPublished - Jun 2009
Externally publishedYes


  • Coagulopathy
  • Liver
  • Rat
  • Toxicogenomics

ASJC Scopus subject areas

  • Toxicology


Dive into the research topics of 'Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy'. Together they form a unique fingerprint.

Cite this